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O r I G I n A L  r e s e A r c h
Glycosaminoglycans in Human and Bovine serum: Detection 
of Twenty-Four Heparan sulfate and chondroitin sulfate Motifs 
Including a Novel Sialic Acid-modified Chondroitin Sulfate 
Linkage Hexasaccharide
hong Lu, Lynda M. McDowell, Daniel r. studelska and Lijuan Zhang
Department of Pathology and Immunology, Washington University school of Medicine, st. Louis, MO 63110, UsA.  
email: ljzhang@wustl.edu.
Abstract: Heterogeneous heparan sulfate and chondroitin sulfate glycosaminoglycan (GAG) polysaccharides are important compo-
nents of blood circulation. Changes in GAG quantity and structure in blood have been indicated in cancers and other human diseases. 
However, GAG quantities and structures have not been fully characterized due to lack of robust and sensitive analytical tools. To 
develop such tools, we isolated GAGs from serum and plasma. We employed liquid chromatography (LC) for GAG quantification and 
LC/mass spectrometry (MS) for GAG structural analysis. Twenty-four heparan and chondroitin sulfate motifs were identified, includ-
ing linkage hexasaccharides, repeating disaccharide compositions, reducing, and non-reducing end mono-, di-, tri-, and tetrasaccharide 
structures. Disaccharides were detectable at picomolar level without radiolabeling or derivitization, so only a few ml of human and fetal 
bovine serum was required for this study. The detection of different reducing end structures distinct from GAG linkage hexasaccharides 
revealed that free GAG chains generated by GAG degradation enzymes co-existed with proteoglycans in serum. In addition, a novel 
sialic acid-modified linkage hexasaccharide was found conjugated to bikunin, the most abundant serum proteoglycan.
Keywords: human and fetal bovine serum, heparan sulfate, chondroitin sulfate, mass spectrometry
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Introduction
Glycosaminoglycans (GAGs) are linear polysac-
charides comprised of glucosamine-/galactosamine-
containing repeating disaccharides. Two major types 
of GAGs, heparan sulfate (HS) and chondroitin 
sulfate (CS), are produced by most animal cells.1 
Because of their differential sulfation, these linear 
polysaccharides are the most information dense 
biopolymers found in nature. GAGs are generated 
during the biosynthesis of protein/GAG conjugates 
known as proteoglycans. The biological functions of 
proteoglycans are largely determined by their GAG 
chains. Rapid turnover2 and structure diversity gen-
erated by both biosynthesis and post biosynthesis 
editing allow GAGs to regulate a myriad of signaling 
pathways.3 Many proteoglycans, such as syndecan, 
endocan, and glypican, and GAG structure-editing 
enzymes, such as heparanase, sulfatases, and hyal-
uronidases, are regarded as potential cancer diag-
nosis/prognosis markers or treatment targets4–11 
GAGs interact with hundreds of plasma proteins,12 
including growth factors, cytokines, chemokines, 
proteases, protease inhibitors, coagulant and antico-
agulant proteins, complement proteins, lipoproteins, 
and lipolytic enzymes.13,14 More than 95% of plasma 
GAGs form complexes with plasma proteins.15 The 
ability to quantify changes in blood GAG structures 
will advance the understanding and diagnosis of 
human diseases.
Knowledge of blood circulating GAGs has accu-
mulated over the last 50 years.16 CS represents the 
major GAG in blood circulation. Other serum GAGs 
include HS, keratan sulfate, and hyaluronan. The rela-
tive amount of HS and keratan sulfates varies greatly 
in patients.17,18 Each of these GAGs is heterogeneous 
with respect to molecular size, disaccharide composi-
tion and sulfate content. Numerous analytical methods 
such as cellulose acetate membrane electrophoresis, 
paper chromatography, gas chromatography, affin-
ity chromatography, HPLC, capillary electrophoretic 
analysis have been developed and applied to quantita-
tive, qualitative, and structural analysis of GAGs.19,20 
However, plasma GAG structures have not yet been 
fully characterized due to a general lack of robust and 
sensitive analytical tools. There are no standardized 
methods for serum/plasma GAG isolation and quanti-
fication. Moreover, when GAGs are co-purified with 
their protein binding partners, their quantification, 
biological activity, and structural analysis can be 
compromised or impaired.17
GAG fine structure is traditionally assessed by 
analyzing repeating disaccharide compositions. 
GAG disaccharides are obtained by either chemical 
or enzymatic depolymerization of GAG chains 
followed by gel filtration chromatography to sepa-
rate disaccharides from salt, mono-, tri-, and other 
oligosaccharides and undigested materials. GAG 
disaccharides have been separated based on charge, 
position of sulfate groups and uronic acid composi-
tion by anion exchange HPLC, reverse phase HPLC, 
capillary electrophoresis, and fluorophore-assisted 
carbohydrate electrophoresis (FACE).21–24 Thus far, 
twenty-three HS disaccharides3 and twenty-five CS 
disaccharides,16 derived from a variety of biologi-
cal sources, have been described. GAG disaccha-
ride composition analysis can quantify GAGs and 
provide structural information.22,25 However, these 
methods are critically dependent on a comparison of 
retention times relative to authentic standards which 
are sometimes difficult to obtain. Moreover, inter-
pretation of the chromatograms can be problematic 
due to contaminants and/or the presence of unknown 
saccharide peaks.
Mass spectrometry (MS) has emerged as the 
tool of choice for GAG disaccharide, oligosaccha-
ride, and GAG sequence analysis.26–39 Electrospray 
ionization mass spectrometry (ESI MS) utilizes a 
flowing stream containing the analyte, provides for 
very gentle ionization, and detects all ions simul-
taneously. Reverse phase HPLC coupled with ESI-
MS greatly benefits GAG disaccharide analysis. 
The unique elution times of the disaccharides from 
capillary HPLC plus the mass/charge (m/z) values 
obtained from MS provide enough information to 
assign each disaccharide unambiguously without 
the use of standards.36,37
In this study we isolated serum and plasma GAGs 
from a few ml of human and fetal bovine serum (FBS) 
and employed LC/MS for GAG structural analysis. 
We detected twenty-four HS and CS structural motifs, 
including linkage hexasaccharides, repeating disac-
charide compositions, reducing, and non-reducing 
end mono-, di-, tri-, and tetrasaccharide structures. In 
addition, a novel sialic acid-modified linkage hexas-
accharide was found conjugated to bikunin, the most 
abundant serum proteoglycan.
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Material and Methods
Materials
DEAE-Sephacel (Sigma I-6505) was washed three 
times in 5 volumes of 2.0 M NaCl, 0.01% Triton 
X-100, 20 mM NaAc pH 6.0, five times in 5 volumes 
of water, and then suspended 1:1 in water before use. 
FBS was purchased from Sigma, Hyclone, and Medi-
atech, Normal human whole blood samples were col-
lected into either regular tubes for serum preparation 
or two 4 ml vacutainers containing K3EDTA (1.6 mg 
EDTA per ml blood) for plasma preparation, and cen-
trifuged at 1500 g for 10 min. Serum and plasma were 
immediately stored at −80 °C before use.
Preparation of metabolically-labeled35 
s-sulfate hs
Nine CHO cell lines, including CHO K1, CHOF17, 
CHOF17.3, CHOK1.5, CHOK1.N7, CHOPPP6, 
3OST-1-, 3OST3A-, and 3OST-5-expressing CHO 
lines established in Dr. Esko,40,41 Dr. Rosenberg,42–44 
and Dr. Liu’s45 laboratories, were metabolically 
labeled with35 S-sulfate using the published proto-
cols.46,47 GAGs were purified and pooled from the 9 
CHO cell lines. CS was removed by chondroitinase 
ABC digestion and HS was used in some experiments 
to assess the recovery of GAGs from serum and 
plasma samples. CHO HS has ∼0.8 sulfate per disac-
charide, which is comparable to the sulfation degree of 
plasma GAGs. We used the 9 CHO cell lines because 
together they might represent a variety of GAG struc-
tures, which allow a fair estimation of the recovery of 
GAGs from serum and plasma samples.
Isolation of proteoglycan core protein 
peptide-containing GAGs
We isolated serum GAG chains from proteoglycans 
and GAG-binding proteins by exhaustive digestion 
with Streptomyces griseus protease (Sigma P5147): 
A protease stock solution (2 ml), containing 1 mg/ml 
protease, 1.92 M NaCl, and 0.24 M NaAc, pH 6.5, 
was added to 10 ml serum solution containing 5 ml 
FBS or human serum plus 5 ml of water. The digestion 
was performed overnight at 37 °C. The sample was 
filtered (0.2 µm). The filtrate was diluted with 20 ml 
of water and the pH and Triton X-100 concentration 
were adjusted to 6 and 0.01%, respectively. The sam-
ple was loaded onto a 0.5 ml DEAE-Sephacel column 
pre-equilibrated with 12 ml of 0.25 M NaCl, 0.01% 
Triton X-100, 20 mM NaAc, pH 6.0 and the column 
was washed with 30 ml of the same equilibrating buf-
fer. GAGs were eluted with 2.5 ml 1 M NaCl in 0.01% 
Triton X-100, 20 mM NaAc, pH 6.0, precipitated with 
10 ml of ethanol, and incubated at 4 °C overnight. The 
GAG ethanol precipitate was collected by centrifuga-
tion (16000 g for 10 min), washed with 1 ml of 75% 
ethanol, collected by centrifugation (16000 g; 10 min), 
and suspended in 200 µl water and stored at 4 °C for 
further analysis. The proteoglycan GAG chains col-
lected in this manner were each expected to be cova-
lently attached to a residual peptide that derived from 
the core protein after the protease digestion.
Isolation of proteoglycan core peptide-free 
GAGs
GAGs prepared as above were freed of their resid-
ual core peptide by a β-elimination reaction fol-
lowed by DEAE-Sephacel purification. In brief, 
100 µl of 1M NaBH4 in 0.5M NaOH was added 
to 100 µl GAG sample and incubated at 4 °C for 
24 h (This treatment cleaves GAG chains from pro-
teoglycan core protein peptides). The borohydride 
was then destroyed by adding 20 µl of glacial HAc 
to the sample. One ml of water and 5 µl of 1 mg/ml 
phenol red were added to the sample to monitor 
pH. The acidic sample (yellow) was neutralized 
with 2.0 M NaOH until the sample turned pinkish. 
The pH was checked by applying 1 µl of sample 
to pH paper allowing adjustment to pH 6 by addi-
tion of 1 M HAc. DEAE-Sephacel slurry (100 µl, 
beads to water 1:1) was added to the β-eliminated 
GAG samples. The maximum sample and DEAE-
Sephacel interaction was achieved by inversion for 
at least 5 min on a rocker platform (Using radio-
labeled GAGs as a tracer, we found that complete 
absorption of GAGs to DEAE-Sephacel beads took 
less than 2 min). The sample was microcentrifuged 
at 16000 g for 1 min. The supernatant was aspi-
rated and the beads were washed three times with 
1 ml 0.25 M NaCl, 0.01% Triton X-100, 20 mM 
NaAc pH 6.0 by re-suspension and microcentrifu-
gation (1 min). The GAGs were pooled from the 
supernatants by four successive 100 µl 1.0 M NaCl, 
0.01% Triton X-100, 20 mM NaAc pH 6.0 elution 
steps. The pooled sample was microcentrifuged at 
16000 g for 1 min to pellet any carryover beads and 
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the supernatant was transferred to a new 1.5-ml 
tube. The GAGs were precipitated by adding 10 µl 
of 20 mg/ml glycogen and 1.1 ml of 100% etha-
nol to the supernatant for at least 2 h at 4 °C. The 
sample was microcentrifuged at 16000g for 15 min 
and the supernatant was aspirated. The pellet was 
washed with 0.5 ml of 75% ethanol by a quick vor-
tex/spin cycle. The GAGs in the dried pellet were 
dissolved in 100 µl of water in a siliconized tube 
and stored at 4 °C for further analysis.
GAG quantification
This assay has been described in detail previously.48 
The steps are acid hydrolysis, sodium boro-
hydride reduction, precolumn derivatization with 
O-phthaldialdehyde (OPA) and 3-mercaptopropionic 
acid (3 MPA), and reversed phase HPLC separation 
with fluorescence detection of the isoindole 
derivatives. GAG aliquots containing 6 nmol 
of norleucine as an internal standard are dried in 
pyrolized glass vials (Agilent, Palo Alto, CA, part 
5181-8872) before hydrolysis with HCl vapor in N2 
gas at 100 °C for 3 hours. The samples are rehydrated 
in 45 µl of 0.56% NaBH4 to reduce the glucosamine 
and galactosamine liberated by acid hydrolysis into 
glucosaminitol and galactosaminitol, respectively. 
After 3 hours or overnight at room temperature, the 
reaction is terminated by adding 5 µl of 2N acetic 
acid to each vial. A 5-µl aliquot of each hydrolyzed 
and reduced sample is transferred to a fresh auto-
sampler insert vial for precolumn derivatization 
with 35 µl of 7.5 mM OPA, 375 mM 3 MPA, in 
0.4 N borate adjusted to pH 9.3 with NaOH. Half 
of this reaction mixture is injected onto a 4.6 × 250 
mm C-12 column, a Synergi 4 µ MAX-RP 80 Å 
(Phenomenex, Torrance, CA, part 00G-4337-E0), 
heated to 35 °C. The column was equilibrated 
with Buffer A, consisting of 0.05 M (monobasic 
and dibasic) sodium phosphate, pH 7.2 in 25% 
methanol, at a flow rate of 0.8 ml/min. Buffer B 
consisted of methanol/water/tetrahydrofuran at 
70:30:3 volume ratios. After injection, Buffer B is 
increased from 0 to 8% by a linear gradient between 
0 and 3 min, is maintained at 8% between 3 and 
18 min, at 55% between18 and 30.5 min, at 100% 
between 30.5 and 32.5 min, and at 0% between 
32.5 and 35 min. A 5 min post-run interval at 0% 
B precedes the initiation of the next precolumn 
derivatization injection sequence. The fluorescent 
derivatives of glucosaminitol, galactosaminitol, 
and the amino acids contained in the GAG 
preparations were excited at 337 nm and detected 
at 454 nm. Quantification of the GlcN and GalN 
peaks was based on calibration curves derived from 
10 external standards ranging from 2.5 pmol to 1280 
pmol (y = 2.085 × −22.59, r2 = 0.997 for GlcN and 
y = 2.085 × −22.59, r2 = 0.9958 for GalN).
enzymatic degradation of GAGs
Heparitinase I (EC 4.2.2.8), heparitinase II (EC 
4.2.2.8), heparinase (EC 4.2.2.7), chondroitinase 
ABC (EC 4.2.2.4), chondroitinase ACII (EC 4.2.2.5), 
CS 4-O-sulfatase (EC 3.1.6.9), and CS 6-O-sulfatase 
(EC 3.1.6.10) were purchased from Seikagaku. 
Heparitinase IV was a kind gift from Dr. Yoshida, 
Seikagaku Corporation. The enzymes 2-O-sulfatase 
(S1062), ∆4, 5-glycuronidase (G9028), and α (2→
3,6,8,9) sialidase (N2876) were purchased from 
Sigma-Aldrich. HS and CS disaccharide standards 
were purchased from Sigma-Aldrich and Seikagaku. 
The disaccharides were dissolved in water to make 
1 mM stock solutions and the concentrations were 
confirmed by GAG quantification.48 All enzymatic 
GAG digestions were performed at 37 °C. For 
HS digestions, GAGs were incubated in 100 µl of 
digestion solution containing 5 mM NH4Ac pH 7.0, 
0.125 mM CaCl2, and 0.33 mU each of heparin lyase 
I, II, III and IV. For CS digestions, GAGs were incu-
bated in 100 µl of digestion solution containing 5 mM 
ammonium acetate pH 7.0 and 1 mU chondroitinase 
ABC. Combined HS and CS digestions were in 
100 µl of digestion solution containing 0.33 mU of 
each heparin lyase, plus 1 mU chondroitinase ABC. 
Digestion was monitored by increased absorbance at 
232 nm by using a Spectra MAX M2 plate-reading 
spectrophotometer (Molecular Devices, Sunnyvale, 
CA) with the temperature of the plate chamber set 
at 37 °C. For exhaustive digestions, the digests were 
incubated at 37 °C overnight after adding another 
100 µl of digestion buffer and enzymes. The same 
heparin lyase buffer was used for all sulfatases and 
∆4, 5-glycuronidase digestions. The sialidase diges-
tion was carried out overnight in a buffer contain-
ing 25 mM NH4Ac pH 5.0 with 10 mU of sialidase. 
The digests were lyophilized and reconstituted in 
10 µl water. Unless otherwise indicated, 0.5 µl of 
serum heparan sulfate and chondroitin sulfate structures
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digested GAG sample was analyzed by LC/MS as 
described below.
Lc/Ms
An Agilent 1100 series capillary HPLC workstation 
(Agilent, Palo Alto, CA) with Chemstation software 
was used for data acquisition, analysis, and manage-
ment. HPLC separations were performed on a 0.3 × 
250 mm C18 column (Zorbax 300SB, 5 µm, Agilent) 
using a binary solvent system composed of 5% metha-
nol (eluent A) and 90% methanol in water (eluent B), 
both contained 3.5 mM dibutylamine and adjusted to 
pH 5.5 with 2 M HAc. While tetrabutylammonium is 
more commonly used as a reverse phase HPLC ion-
pairing reagent to achieve baseline separation of all 
disaccharides, tetrabutylammonium would interfere 
with MS detection and so we employed dibutylamine 
for this purpose. After injection of 0.5 µl sample, the 
elution profile was 0% B for 7 min, 15% B for 9 min, 
40% B for 11 minutes, and 100% B for 23 minutes. 
The flow rate was 5 µl per minute, and absorben-
cies at 232, 260, and 280 nm were monitored during 
each run. After each run the column was washed with 
90% B for 15 minutes, and equilibrated with 100% 
A for 40 minutes. The capillary HPLC was directly 
coupled to the mass spectrometer. Mass spectra were 
acquired on a Mariner BioSpectrometry Workstation 
ESI time-of-flight mass spectrometer (PerSeptive 
Biosystems; Framingham, MA) in the negative-ion 
mode. Nitrogen was used as a desolvation gas as well 
as a nebulizer. Conditions for ESI-MS were as fol-
lows: nebulizer flow, 1 liter/min; nozzle temperature, 
140 °C; N2 flow, 0.1 liters/min; spray tip potential, 
2.8 kV; nozzle potential, 70 V; and skimmer poten-
tial, 9V. Negative ion spectra were collected by scan-
ning the m/z range 150–1000. During analyses, the 
vacuum was 2.1 × 10–6 Torr. TIC chromatograms and 
mass spectra were processed with Data Explorer soft-
ware version 3.0.
Results
Isolation and quantification  
of GAGs from serum
Our goal was the development of straightforward 
methods that allow quantification and structural 
analysis of serum/plasma GAGs by LC/MS. Our 
application is the discovery and characterization of 
plasma GAG-based disease biomarkers. In preliminary 
experiments, we analyzed commercially available 
heparin, HS, and several structural varieties of CS by 
LC/MS. All disaccharides were easily detected and 
quantified and the disaccharide compositions obtained 
were consistent with literature values based on either 
UV or MS signals (data not shown). In contrast, 
these same methods proved unsatisfactory for the 
analysis of GAGs isolated from animal cells and 
tissues, including FBS. Non-sulfated disaccharides 
could not be detected by either UV or MS. The UV 
signal was obscured by a 232 nm signal produced by 
contaminants in the enzymatically digested GAGs. The 
contaminants also made the non-sulfated disaccharide 
undetectable by MS (data not shown). These results 
are consistent with previous publications that non-
sulfated disaccharides were not detected in digested 
GAGs isolated from different biological sources,44,49,50 
which indicates that GAGs from small biological 
samples need to be further purified to accommodate 
disaccharide composition analysis by LC/MS.
We developed a serum GAG purification procedure 
using FBS as a starting material (see Experimental 
Procedures). We added 35S-labeled HS mixture puri-
fied from 9 CHO cell lines to the serum samples prior 
to GAG isolation to monitor GAG recovery in each 
step. Briefly, we subjected FBS to exhaustive prote-
ase treatment in order to free GAGs from proteogly-
cans and GAG-binding proteins. We then isolated the 
GAGs by column chromatography. Following ethanol 
precipitation, the purified GAGs were subjected to 
β-elimination reaction with NaBH4/NaOH in order to 
free them from residual peptide remaining from the core 
protein. Peptide-free GAGs were isolated by affinity to 
DEAE-Sephacel beads, eluted from the beads, ethanol 
precipitated and resuspended. We recovered more than 
95% of the 35S-HS in our final GAG preparations.
We used the modified procedure to purify GAGs 
from 5 ml samples of FBS, human serum, and EDTA-
anticoagulated human plasma that had been prepared 
from the same blood donor, a portion (10%) of each 
GAG preparation was assayed for GlcN and GalN 
GAG composition using an established reverse phase 
HPLC method with series of GlcN and GalN standards48 
(Fig. 1). These experiments yielded the following 
values: 36.8 µmol of GalN and 6.23 µmol of GlcN per 
ml human serum, 22.6 µmol of GalN and 3.20 µmol of 
GlcN per ml human plasma, and 24.4 µmol of GalN and 
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7.97 µmol of GlcN per ml FBS. Using the observed GAG 
average disaccharide M.W. of 460 for our calculations, 
we estimate that human serum had 17.0 µg/ml CS 
and 2.86 µg/ml of the GlcN-containing GAGs ( HS, 
HA, and KS), human plasma had 10.4 µg/ml CS and 
1.47 µg/ml GlcN GAGs, and FBS had 10.2 µg/ml CS 
and 3.67 µg/ml GlcN-containing GAGs.
Disaccharide analysis of hs and cs 
isolated from FBs
We next conducted a structural analysis of GAGs 
derived from FBS by LC/MS. Proteoglycan core 
peptide-free GAGs were isolated from FBS as 
described in material and methods. A portion (10%) 
of the core peptide-free GAGs was digested with a 
mixture of heparin lyases and a portion of the digested 
(5%) of GAGs was analyzed by LC/MS. The resulting 
UV and MS chromatograms are shown in Figure 2. 
Peak 1 detected by UV was defined as ∆UA-GlcNAc 
(z1 378.1) by MS. Peak 2 detected by UV had two 
disaccharides, ∆UA-GlcNAcS (z1 458.03, z2 228.53) 
and ∆UA-GlcNS (z1 416.07, z2 207.52) based on MS 
analysis. Peak 3 detected by UV were indicated to be 
disulfated disaccharides, ∆UA-GlcNS+1S (z1 496.1, 
z2 247.50) by MS. Peak 4 detected by UV was a tri-
sulfated disaccharide, ∆UA2S-GlcNS6S (z1 576.0, 
z2 287.49) based on MS analysis.
To distinguish ∆UA2S-GlcNS from ∆UA-GlcNS6S 
in peak 3, we treated the heparin lyase digested mixture 
further with ∆4, 5-glycuronidase prior to HPLC-MS 
analysis. The ∆4, 5-glycuronidase enzyme removes 
∆UA from the disaccharides that do not have 2-O-sul-
fated residues.51 In this case we observed a decrease 
in the UV and MS signals in peak 3 (a mixture of 
∆UA2S-GlcNS and ∆UA-GlcNS6S), but not peak 4 
(∆UA2S-GlcNS6S) (not shown), which allows us to 
estimate the relative abundance of ∆UA2S-GlcNS vs. 
∆UA-GlcNS6S in the peak 3.
The CS disaccharide composition of the FBS 
GAGs was determined by treatment of the proteogly-
can core peptide-free GAGs isolated above with chon-
droitinase ABC prior to analysis by LC/MS. The UV 
and MS chromatograms are shown in Figure 3. Sev-
eral species were detected: Nonsulfated disaccharide 
(∆UA-GalNAc, z1 378.1), monosulfated disaccha-


























Figure 1. Quantification of glucosamine (GlcN) and galactosamine 
(Galn) content of GAGs isolated from FBs (red), human serum 
(black), and human plasma (blue). GAGs were purified and then 
digested by acid hydrolysis, reduced with naBh4, and reacted with OPA 
(O-phthaldialdehyde)/3MPA (3-mercaptopropionic acid); a reagent to 
form fluorescent isoindole derivatives of glucosaminitol or galactosamini-
























Figure 2. UV absorbance (dashed line) and TIc (solid line) of a heparin 
lyase digest of FBs GAGs. Peak 1 contains ∆UA-GlcnAc (z1 378.1). 
Peak 2 contains ∆UA-GlcnAc+s1 (z1 458.03, z2 228.53) and ∆UA-
Glcns (z1 416.07, z2 207.52). Peak 3 contains ∆UA2s-Glcns (z1 





























Figure 3. UV absorbance (dashed line) and TIc (solid line) of chondroitinase 
ABc digested FBs GAGs. The most abundant ions found in each peak are 
shown. Peak 1 contains ∆UA-GalnAc (z1 378.1). Peak 2 contains ∆UA-
GalnAc+s1 (z1 458.0, z2 228.5). Peak 3 contains ∆UA-GalnAc+s2 (z1 538.1). 
Peak 4 contains ∆UA-GalnAc-GlcA-Gal-Gal-Xylol+s2 (z2 585.6).
serum heparan sulfate and chondroitin sulfate structures
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538.1 disaccharides (∆UA-GalNAc+2S, z1 538.1), as 
well as a z2 585.6 corresponding to the linkage hexa-
saccharide ∆UA-GalNAc-GlcA-Gal-Gal-Xylol (plus 
2 sulfates or 1 sulfate and 1 phosphate).
The sulfation positions of the CS disaccharides 
were then determined by treatment of the chondroi-
tinase-treated material with a variety of sulfatases 
prior to HPLC/MS analysis. Unlike the newly cloned 
heparan sulfate 6-Osulfatase,52 chondroitin 4-O- and 
6-O-sulfatases hydrolyze unsaturated sulfated disac-
charides and oligosaccharides produced by chon-
droitinase digestion.53,54 Indeed, we observed that 
chondroitin lyases 4-O-sulfatase digestion decreased 
the sulfated disaccharide UV and MS signals while it 
increased nonsulfated disaccharide UV and MS sig-
nals (data not shown). These results indicate that the 
monosulfated disaccharides were mostly 4-O-sulfated 
at GalNAc residues. The 4-O-sulfate-digested mate-
rial was further treated with CS 6-O-sulfatase and then 
2-O-sulfatase. Each successive treatment reduced the 
monosulfated z1 458.1 signal further, indicating the 
presence of both 2-O- and 6-O-sulfated disaccharides 
in addition to 4-O-sulfated disaccharides in the origi-
nal FBS GAG sample. Disaccharide composition was 
calculated from the observed changes in signal inten-
sity, as described later.
The reducing and non-reducing end 
mono-, di-, tri-, and tetrasaccharide 
structures in FBs
Several non-reducing end species were identified in 
the chondroitinase-treated fractions: Non-reducing end 
mono-sulfated GalNAc (z1 300.05, IC 6374) eluted 
at 3.8 min. Non-reducing end di-sulfated GalNAc 
(z1 380.02 and z2 189.50, IC 1408) eluted at 9.0 min. 
Non-reducing end mono-sulfated disaccharide, GlcA-
GalNAc+1S (z1 476.10), eluted at 7.2 min (IC 677). 
The elution position and m/z values for the mono- and 
di-saccharides were in agreement with the non-reducing 
end structures of CS identified by Midura et al.55
Extracted ion current (XIC) of m/z 556 and 636 
is shown in Figure 4. The two peaks represented two 
reducing end trisaccharides, ∆UA-GalNAc-UA-ol 
(z1 556.07, IC 2658) and ∆UA-GalNAc4S-UA-ol 
(z1 636.15, z2 317.56, IC 2311). ∆UA-GalNAc-UA-
ol eluted at 7.3 min and ∆UA-GalNAc-UA-ol+1S 
eluted at 13.5 min. Chondroitin sulfate 4-O-sulfatase 
treatment eliminated ∆UA-GalNAc-UA-ol+1S sig-
nals (z1 636.15, z2 317.56) and resulted an increase 
in non-sulfated trisaccharide ∆UA-GalNAc-UA-ol 
signal (z1 556.07, data not shown), which indicated 
that there was a 4-O-sulfated GalNAc residue in the 
monosulfated trisaccharide, ∆UA-GalNAc4S-UA-ol. 
The ICs of the trisaccharides were about 21% that 
of the linkage hexasaccharide IC. Thus, a significant 
amount of free CS chains ending in uronic acid co-
existed with proteoglycans in FBS.
We also observed another reducing end tetrasac-
charide ∆UA-GalNAc-UA-GalNAc-ol+1S, and 
a non-reducing end trisaccharide, GalNAc-UA-
GalNAc+3S, in that both had the same mass but 
different elution time and m/z values. The XIC of m/z 
419 is shown in Figure 4b. The 14.1 min peak had z1 
839.26 (IC 63) and z2 419.11 (IC 708) ions, whereas 
the 19.3 min peak had z2 419.05 (IC 1090) and z3 
279.03 (IC 514) ions. No z3 ion was observed at 
14.1 min and no z1 ion was observed at 19.3 min. The 
m/z values, the elution position, and the charge status 
suggested that the 14.1 min peak was the reducing 
end monosulfated tetrasaccharide, ∆UA-GalNAc-























Figure 4. XIc of FBs cs reducing and non-reducing end structures 
from the data presented in Figure 3. A) The XIc of the reducing end tri-
saccharides, ∆UA-GalNAc-UA-oland ∆UA-GalnAc4s-UA-ol. The inserts 
show the z1 for ∆UA-GalnAc-UA-ol and z2 for ∆UA-GalnAc4s-UA-ol. 
B) The XIc of the reducing end tetrasaccharide, ∆UA-GalnAc-UA-Gal-
nAc-ol+s1 (14.1 min peak) and the non-reducing end trisaccharide, 
GalnAc-UA-GalnAc+s3 (19.3 min peak). The inserts show the z2 ions 
observed for each peak.
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was the non-reducing end, tri-sulfated trisaccha-
ride, GalNAc-UA-GalNAc+3 sulfates. To confirm 
this, FBS GAGs were treated with NaBD4 instead of 
NaBH4 to label the reducing end saccharides in the β-
elimination reaction and digested with chondroitinase 
ABC. In that case the 14.1 min peak had a z2 419.61 
instead of z2 419.05, whereas the m/z of the ions in 
19.3 min peak remained the same (data not shown). 
While no internal tetrasaccharides were observed 
after one round of chondroitinase ABC digestion, the 
19.3 min peak was still seen after 4 rounds of chon-
droitinase ABC digestion, indicating that the trisac-
charide was resistant to enzymatic depolymerization. 
However, its ion intensity was reduced with repeated 
chondroitinase ABC digestions, and its ion reduction 
was accompanied by an increase in TIC of di-sulfated 
GalNAc (z1 380.02 and z2 189.50) (data not shown). 
Together these observations suggest that the 19.3 min 
peak represents a trisaccharide that had 2 sulfates at 
its non-reducing end GalNAc residue.
cs Linkage hexasaccharides
After chondroitinase ABC digestion of FBS GAGs, 
the following known linkage hexasaccharides were 
observed: 1. Non-sulfated hexasaccharide (z2 505.6, 
IC 599), eluted at 7.1 min. 2. Mono-sulfated hexa-
saccharide (z2 545.6, IC 2366), eluted at 13.0 min. 
3. Di-sulfated hexasaccharide (z2 585.6, IC 1.3 × 104), 
eluted at 18.6 min. 4. Tri-sulfated hexasaccharide 
(z2 690.2 = 625.2 + 1 dibutylamine (DBA), z3 
416.74, IC 327), eluted at 20.2 min. The structure 
of the most abundant di-sulfated linkage hexasac-
charide (z2 585.6, IC 1.3 × 104) was confirmed by 
the following experiment: The GAG sample was 
first digested with chondroitinase ACII, a treatment 
which cleaves linkage hexasaccharides into di- and 
tetrasaccharides. Indeed, the hexasaccharide peak 
disappeared and a new z1 713.1 peak appeared (data 
not shown). The z1 713.1 ion was likely the tetra-
saccharide ∆UA-Gal-Gal-Xylol, plus one sulfate or 
phosphate. Alkaline phosphatase treatment did not 
affect the z1 713.1 ion. However, further digestion 
with CS 4-O-sulfatase led to the appearance of a 
new species, z1 633.1 and partial disappearance of 
z1 713.1 ion. Z1 633.1 ion corresponds to a non-sul-
fated linkage tetrasaccharide (∆UA-Gal-Gal-Xylol). 
These results indicate that the most abundant link-
age hexasaccharide was a di-sulfated hexasaccharide 
(∆UA-GalNAc)+1S-(GlcAc-Gal-Gal-Xylol)+1S. 
To further confirm the identity of the linkage hexa-
saccharides, FBS GAGs were treated with NaBD4 
instead of NaBH4 in β-elimination reaction prior to 
chondroitinase ABC digestion and LC/MS analysis, 
all the putative linkage hexasaccharides underwent 
a +1 mass increase (data not shown), indicating that 
they all derived from the reducing end of CS chains.
Theoretically, every non-reducing end uronic 
acid double bond in both repeating disaccharides 
and linkage hexasaccharides should produce the 
same UV absorbance. The summed UV signal of 
all the disaccharides divided by the summed UV 
signal of the linkage hexasaccharide gave an esti-
mated average chain length of 12 disaccharides for 
FBS CS.
Identification of sialic acid-containing  
cs linkage hexasaccharides
The most striking difference between FBS and human 
serum CS was a 20-fold higher level in human serum 
of an ion with a z2 731.2 (IC 110 vs. 2672) and z3 
487.1 (IC 98 vs. 1605) (Fig. 5). This ion eluted at 
20.1 min, between di- and tri-sulfated linkage hexas-
accharides. It was not observed in commercial CS-A, 












































Figure 5. Significant increase of a novel ion with a z2 731.2 in human 
serum. The XIc of the ions, z2 731.2 and other linkage hexasaccharides 
(z2 505.6, 545.6, 585.6, 690.2 = 625.6 + 1DBA) in and FBs (upper panel) 
and human serum (lower panel. The inserts show the most abundant 
ions observed for each peak.
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with chondroitinase ABC, which indicates that it is 
not generated during CS degradation. To determine 
whether this novel ion species was derived from a 
serum proteoglycan, we exhaustively digested human 
serum with protease and isolated the GAGs. Half of 
the GAG sample was treated with NaBH4 to remove 
the core protein peptides. Both the NaBH4-treated and 
unreduced GAG fractions were then digested with 
chondroitinase ABC and analyzed by capillary HPLC 
coupled MS. TIC chromatograms for both GAGs are 
shown in Figure 6. The major peak in both chromato-
grams eluting at 8.3 min represents the mono-sulfated 
repeating disaccharides (z1 458.03 and z2 228.54). 
In the chromatograph of the reduced GAGs, the T1 
peak was identified as the di-sulfated linkage hexa-
saccharide which has a natural molecular weight of 
(585.6228 × 2 + 2) – 2 = 1171.25 and the T2 peak 
is the novel ion with a molecular weight 1464.36 
(731.1787 × 2 + 2). Neither T1 nor T2 were present in 
the chromatograph of the non-reduced GAGs. Instead 
we observed a major peak, T3 (molecular weight 
2001.54 (499.3855 × 4 + 4), and a minor peak, T4 
(molecular weight 2292.65 (457.5291 × 5 + 5).
Assuming the novel ion T2 is derived from a 
GAG linkage saccharide, with a natural molecular 
weight of 1464.36 – 2 = 1462.36, then the molecular 
difference between peak T3 and the linkage hexas-
accharide T1 (2001.54–1171.25 = 830.29) is equal 
to the molecular difference between peak T4 and the 
novel ion T2 (2292.65–1462.36 = 830.29). This sug-
gests the two unreduced ions, T3 and T4, could be 
attached to a common peptide of molecular weight 
830.29. We searched the MS protein databank (http://
www.proteomeconsortium.org) for appropriately 
sized peptides bearing at least one Ser-Gly consen-
sus sequence, and identified a logical candidate pep-
tide, QEEEGSGGG (830.29 + 18.01), derived from 
bikunin, the most abundant CS proteoglycan in nor-
mal human serum. Together these observations indi-
cate that large fractions of the CS species we have 
resolved, including the novel ion, are derived from 
the bikunin proteoglycan.
The mass difference between the novel ion and 
the disulfated linkage hexasaccharide ion, 291.1 amu, 
immediately suggested that the novel ion could be 
a disulfated linkage hexasaccharide modified by the 
addition of a sialic acid residue. Moreover, the elution 
of the novel ion, between di- and tri-sulfated linkage 
hexasaccharides is consistent with the extra negative 
charge which sialic acid would provide. While sialic 
acid modified linkage hexasaccharides have never 
been reported, Wakabayashi et al, have identified a 
proteoglycan linkage-like tetrasaccharides with 3-O-
sulfated GlcA and sialic acid modified Gal residue.56 
Thus, we treated chondroitinase ABC digested human 
serum GAGs with sialidase and compared the results 
to non-sialidase treated controls by LC/MS. Neither 






























Digested CS after β-elimination
Figure 6. Bikunin, the most abundant csPG in blood circulation, 
was covalently linked to linkage hexasaccharide and the novel ion. 
TIc of chondroitinase ABc digested human serum GAGs before 
(black line) and after β-elimination reactions (red line). Inserts show 
the most abundant ions for T1, T2, T3, and T4 peaks. The pep-
tide molecular weight (830.29+18.01) was derived based on the 
molecular weight changes from (T3 peak) to (T1peak) and from (T4 
peak) to (T2 peak). Therefore, the same bikunin peptide, QeeeGs-
GGG, with a molecular weight of 830.29+18.01 was removed by 
the β-elimination reaction from both linkage hexasaccharide and 
the novel ion.












Figure 7. sialidase treatment eliminated the novel ion. XIc of z2 585.6, 
z2690.2, and the novel ion, z2 731.2, before (black line) and after (red 
line) sialidase treatment. The novel ion, z2 731.2, was no longer detect-
able after sialidase treatment whereas the trisulfated hexasaccharide ion 
(690.2) was unaffected and the percentage of di-sulfated hexasaccha-
ride ion was increased.
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z2 731.2 nor z3 487.1 ions survived the treatment, 
while all other linkage hexasaccharide ions remained 
(Fig. 7). This result confirmed that the novel ion is 
derived from a linkage hexasaccharide modified with 
a sialic acid moiety.
FBs and human serum hs and cs 
disaccharide compositions
We next sought to use the LC/MS protocol to quantify 
the disaccharide composition of FBS and human 
serum GAGs. However, the TIC signals derived 
from the LC/MS system cannot be used directly for 
disaccharide composition analysis: Sulfated disac-
charides are eluted from the HPLC at a higher level 
of methanol than the non-sulfated disaccharides, 
and the greater desolvation that accompanies the 
higher methanol levels results in higher sensitivity 
for MS detection. We circumvented this problem 
by employing a series of HS and CS standard 
disaccharides.
To this end, UV and MS signals from a mixture of 
five different HS disaccharides were analyzed over a 
20-fold concentration range (from 50 to 1000 pmol 
per injection) (Fig. 8). Similar experiments were also 
conducted by using a mixture of five different CS 
disaccharides (data not shown). For all volumes and all 
HS and CS disaccharides, the average UV area/pmol 
disaccharide was 9.06 ± 1.4 mAU (mean ± standard 
deviation) irrespective of their structures and elution 
position. The MS signals for equimolar amount of 
disaccharides were much higher for sulfated than for 
nonsulfated disaccharides. However, the ratio of UV 
to MS signal intensity for each disaccharide was con-
stant over the range of concentrations analyzed. These 
ratios, derived from pure disaccharide standards, are 
shown in Table 1. The formula, IC multiplied by UV/
IC equalizing factor, was used to normalize the MS 
signal for disaccharide quantification purposes. In 
our system, the MS detection limit was ∼1 pmol for 
-GlcNAc/∆UA-GalNAc and ∼100 fmol for ∆UA2S-
GlcNS6S. In contrast, the UV detection limit, defined 
as peak heights at 3 times baseline noise levels, was 
10 pmol for all disaccharides.
Based on the equalizing factors, HS and CS 
disaccharide compositions were calculated for FBS 
and human serum (Table 2). Typical blank TIC 
background was 10 ± 5. In principle, any GAG ions 
with a TIC signal above 50 can be identified by the 
LC/MS method from its stable isotope distribution 
pattern and unique elution position. In all we have 
detected twenty-four distinct heparan sulfate and 
chondroitin sulfate components from FBS and human 
serum (summarized in the Table 2). There were still a 
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Figure 8. Quantification of HS disaccharide standards by LC/MS. Volumes 
of 0.05, 0.10, 0.50, or 1.0 µl of a mixture of disaccharide standards were 
analyzed. Both the hPLc UV absorbance (dashed lines) and Ms TIc (solid 
lines) increase with increased analyte. Peak 1 is ∆UA-GlcnAc (z1 [mass – 1 
proton] = 378.1). Peak 2 is ∆UA-Glcns (z1 416.1). Peak 3 contains both 
∆UA2s-Glcns (z1 496.1) and ∆UA-Glcns6s (z1 496.1). Peak 4 is ∆UA2s-
Glcns6s (z1 576.0). The quantitative data are summarized in Table 1.
Table 1. Ms signal equalizing factors (the ratio of TIc/pmol 
to UV area/pmol) for hs and cs disaccharides.
Disaccharide standards Mean TIc/UV area*
∆UA-GlcnAc 0.761 ± 0.076
∆UA-Glcns 2.019 ± 0.066
∆UA-Glcns6s/∆UA2s-Glcns 3.659 ± 0.543
∆UA2s-Glcns6s 4.431 ± 0.426
∆UA-GalnAc/∆UA-GlcnAcβ 0.841 ± 0.071
∆UA-GalnAc4s/∆UA-GalnAc6s 2.017 ± 0.125
∆UA2s-GalnAc4s 4.128 ± 0.224
*Average results from injection volumes of 0.05, 0.1, 0.5, and 1.0 µl. For 
all volumes and all disaccharides, the average UV area/pmol disaccharide 
was 9.06 ± 1.4 mAU (mean ± standard deviation). Ms signals are higher 
for sulfated disaccharides than for equimolar amounts of nonsulfated 
disaccharides. This is due to an increased percentage of organic solvent 
in the elution at later times and the increased ionizability of more highly 
charged sulfated disaccharides.
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Heparan sulfate
(Hs Disaccharide %.  
B:FBs, H:human serum)




























z1 576.01, z2 287.49 z3 191.32 19.3 2105 1167
21.70% 16.60%
chondroitin sulfate
(cs Disaccharide %. B:FBs, H:human serum)
∆UA-GalnAc  
(B6.3%, h2.8%)
















z1 538.06, z2 268.51,z3 178.67 14.9 14428 1239
2.60% 0.13%
GalnAc+s1 z1 300.05 3.8 6674 2165
1.20% 0.22%
GalnAc+s2 z1 380.02, z2 189.50 9 2750 186
0.46% 0.02%
GlcA/IdoA-GalnAc+s1 z1 476.10, z2 237.53 7.2 677 520
0.12% 0.05%
∆UA-GalnAc-UA-ol z1 556.07 7.3 2658 259
0.48% 0.26%
∆UA-GalnAc4s-UA-ol z1 636.15, z2 317.56 13.5 2311 319
0.42% 0.03%
∆UA-GalnAc-UA-GalnAc-ol z1 839.26, z2 419.11 14.1 1190 88
0.21% 0.01%
(Continued)
Table 2. Twenty four FBs and human serum hs and cs mono-, di-, tri-, tetra-, and hexasaccharides.
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few minor unidentified ions in both FBS and human 
serum GAGs that are under current investigation.
Discussion
This report describes a LC/MS method for the analy-
sis of GAGs isolated from serum and plasma. Samples 
undergo extensive proteolysis to free GAGs from their 
respective proteoglycans and GAG-binding proteins, 
treatment with NaBH4 or NaBD4 to eliminate residual 
core protein peptides and to tag reducing ends of free 
GAGs, and digestion with a variety of GAG-specific 
enzymes to identify mono-, di, tri-, tetra-saccha-
rides, linkage hexasaccharides, and other oligosac-
charides. Reverse phase capillary HPLC is used to 
separate GAG mono-, di-, tri-, and oligosaccharides 
according to charge and structure and to remove 
contaminating salts and undigested material, and the 
resulting fractions are simultaneously analyzed by 
both UV and MS. GAG structures are identified on 
the basis of UV absorbance, m/z values, and HPLC 
retention times. Sulfatases are used to distinguish 
among disaccharide isomers. Twenty-four distinct 
HS and CS components including reducing end struc-
tures and a novel sialic acid-modified chondroitin 
sulfate linkage hexasaccharide were identified from 
FBS, human serum, and human plasma. The purified 
serum/plasma GAGs were quantified by a previ-
ously-reported reversed-phase HPLC method that 
quantifies GlcN and GalN content simultaneously48 
chondroitin sulfate
(cs Disaccharide %.  
B:FBs, H:human serum)
Observed ions elution time TIc and % of TIc
FBs Human




















z2 731.22, z3 487.12, z4 365.08 20.1 208 4277
0.04% 0.44%
(Fig. 1). It was reported that CS content is higher 
in serum because CS is released from platelets dur-
ing coagulation process.57 Indeed, CS levels were 
substantially greater in the human serum sample 
(17.0 µg/ml) than in plasma (10.4 µg/ml) derived 
from the same blood sample. We also observed 
greater GlcN-containing GAGs in the human serum 
(2.86 µg/ml) than in the plasma (1.47 µg/ml), which 
suggests that GlcN-containing GAGs might also be 
released during the coagulation process. There is a 
wide disparity in previous estimates of human serum 
and plasma GAG concentrations18,58 which may 
reflect differences in the methods used for GAG iso-
lation and quantification. The values we observed in 
human serum (20 µg/ml) and plasma (12 µg/ml) are 
at the high end of literature values, likely due to the 
exhaustive protease digestion we employed to disso-
ciate GAGs from their respective proteoglycans and 
GAG-binding proteins.
Previous use of LC/MS for the analysis of GAGs 
in biological samples failed to detect non-sulfated 
disaccharides and underestimated mono-sulfated 
disaccharides.44,50,59 The modifications we have 
introduced in the GAG isolation steps allowed 
us to detect non-sulfated disaccharides and other 
oligosaccharides via LC/MS. The capillary HPLC 
step is particularly important for the removal of salts 
that interfere with MS-based GAG analysis. Since the 
UV and MS signals we obtained were linear over a 
Table 2. (Continued )
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wide range (Fig. 8), we calculated GAG disaccharide 
composition using equalizing factors, a technique 
previously established for tandem ESI-MSn 27–29 
and LC/MS.36,37 However, there are limitations to 
such quantifications. The estimation of quantities 
of 24 detected components in Table 2 relied on 
“equalizing factors” that were derived from dose 
curves for pure disaccharide standards. Because these 
standards were assayed pure and not mixed in with 
complex serum/plasma GAG samples that contain 
contaminants affecting ionization thus MS detection, 
these equalizing factors do not account for possible 
quenching of analyte ionization. In addition, MS 
detection sensitivity could change during a run and 
between different runs in the same day, which made 
this method a more qualitative than quantitative one.
Using this method, we have identified a novel 
sialic acid-modified CS linkage hexasaccharide, pri-
marily in GAGs derived from human serum. We have 
also observed small amounts of sialic acid-modi-
fied linkage hexasaccharides in GAGs derived from 
mouse tissues and mouse growth plates (Zhang, L., 
unpublished results). Previously, CS linkage hexas-
accharides from different tissues and cell lines were 
characterized via both NMR and enzymatic sequenc-
ing approaches by Dr. Sugahara’s group,60 and CS 
linkage hexasaccharides from rat chondrosarcoma 
cells were analyzed using a combination of Progel-
TSK G2500 and CarboPac PA1 chromatography 
steps in conjunction with monosaccharide analyses 
by Shibata et al.61 Neither of those studies identi-
fied a sialic acid modified linkage hexasaccharide. It 
is possible that sialic acid-modified GAGs have not 
been detected before because they occur in low abun-
dance. Proteins that bind to sialic acid are involved in 
regulating many biological processes.62 Thus, sialic 
acid-modified CS may provide GAGs with unique 
biological functions.
The estimation of GAG molecular weights has 
long been difficult, complicated by the effects of chain 
length and sulfation heterogeneity and conforma-
tional differences among the GAGs. Number-average 
mean molecular weight values have been obtained 
by osmometry, and weight average mean molecular 
weight values have been obtained by viscometry and 
light scattering, but these methods require relatively 
large amounts of material. Several groups have used 
heparin, dermatan sulfate, and CS to estimate their 
molecular weights by intrinsic viscosity and light 
scattering intensity, and subsequently these character-
ized GAGs were used as molecular weight standards 
for gel electrophoresis or gel filtration chromatogra-
phy-based biological GAG chain length estimation. 
However, the hydrodynamic size of GAGs was found 
to be influenced by the sulfation isomer composi-
tion of the chains.63 Moreover, heparin and derma-
tan sulfate samples with the same molecular weight 
values as observed by gel filtration chromatography 
had different intrinsic viscosity and different radius 
of gyration when right-angle laser light scattering, 
refractometer and viscometer were used for triple 
on-line detections.64 Thus, the molecular weight mea-
sured by these approaches has limited accuracy.
Number-average molecular weight can be esti-
mated if the ratio of GAG reducing or non-reducing 
end saccharide to repeating disaccharides is obtained. 
Desai and Linhardt have used 13C NMR to estimate 
the molecular weight of low molecular weight heparin 
based on the signal strength of reducing end GlcA vs. 
repeating disaccharides.65,66 However, most biological 
GAGs have GlcA-Gal-Gal-Xyl-linkage tetrasaccha-
rides rather than GlcA at the reducing end. Plaas et al67 
have estimated CS average chain length by quantify-
ing the non-reducing end mono- and disaccharides 
vs. repeating disaccharides. However, an unknown 
late eluting peak, which might be a non-reduced tri-
saccharide, was observed but was not included in cal-
culations.55 We have used LC/MS to detect reducing 
end, non-reducing end, and repeating disaccharides 
simultaneously. In principle, CS chain length can be 
estimated by comparing either reducing end or non-
reducing end groups to repeating disaccharide. Since 
we do not have mono- di-, and trisaccharide standards 
to generate proper equalizing factors for quantifying 
non-reducing ends, we compared the ratio of UV sig-
nal intensities of total disaccharides to reducing end 
linkage hexasaccharides. We calculated an average of 
12 disaccharides per CS chain in FBS and 14 disac-
charides per CS chain in human serum. These values 
are quite similar to 15 ± 3 disaccharides per bikunin 
CS chain based on three independent studies using 
several different approaches.68,69 Interestingly, bikunin 
CS chains derived from a patient with septic shock and 
measured by MALDI-MS were 6 disaccharides lon-
ger than those derived from a normal patient.70 Thus, 
serum GAG chain length could vary with respect to 
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physiological conditions. We could not analyze the 
average HS chain length: The heparin lyase III used 
in the isolation procedure cleaves HS linkage hexas-
accharides into di- and tetra-saccharides.71 However, 
no FBS or human serum HS linkage tetrasaccharides 
were observed based on LC/MS analysis. This could 
indicate that serum HS chains are much longer than 
the CS chains, and/or the MS signals emitted by the 
linkage tetrasaccharides are weak due to a lack of sul-
fation in the HS linkage tetrasaccharides.72
The reduction of free GAGs by either NaBH4 or 
NaBD4 terminates the ends of free GAGs with an alco-
hol group while further enzymatic digestion leaves a 
residual aldehyde at the repeating disaccharides. This 
allows the detection of reduced and un-reduced GAG 
structures simultaneously by the LC/MS method 
(Table 2). Such detection showed the coexistence of 
free GAGs and proteoglycans in serum. Free GAGs 
would likely be produced in vivo. Heparanase (endo-
β-glucuronidase) cleaves HS at GlcA-GlcNAc/SO3 
bonds5 and also degrades CS in vitro (Zhang, L, 
unpublished observation). Free GAGs terminating 
with GlcA (Indicated with a GlcA-OH end in Fig. 4a) 
may have been generated from proteoglycans by 
extracellular heparanase. Hyaluronidase (endo-β-N-
acetylhexosaminidase) cleaves hyaluronan,73 as well 
as CS and DS in vitro.74 A CS specific hyaluronidase 
has been characterized recently.75 Free GAG chains 
with GalNAc at reducing end (Indicated by a Gal-
NAc-OH end in Fig. 4b) may have been generated 
from proteoglycans by such hyaluronidases.
The GAGs present in the serum are derived from 
many different cells and tissues including the liver,76 
platelets,57 endothelial cells,77 and malignant cells.78 
Specific GAG structures are the results of modifica-
tions that occur during proteoglycan biosynthesis, in 
the extracellular matrix, and in the plasma by the GAG 
editing enzymes. Thus, the spectrum of serum GAG 
quantity and structures is a reflection of physiologi-
cal state, and is therefore a potentially rich source of 
biomarkers for the assessment of human health and 
disease. To overcome intrinsic difficulties in quan-
tifying GAG di- and oligosaccharide changes by the 
LC/MS method for biomarker discoveries, we recently 
adapted the Glycan Reductive Isotope Labeling (GRIL) 
technique.38 The technique involves enzymatic diges-
tion of purified GAGs using chondroitinase and/or 
heparin lyases, followed by reductive amination of the 
reducing ends of the disaccharides with aniline for one 
sample and deuterated (D5)-aniline for the other sam-
ple. The addition of the regular aniline group adds 77 
amu to the mass of the free molecular ion ([M-H]−1), 
whereas D5-aniline group adds 82 amu. Thus, normal 
and diseased biological samples tagged with different 
isotopically labeled anilines can be mixed and analyzed 
simultaneously to yield quantitative or ratiometric 
comparisons. This analysis overcomes the problematic 
run-to-run and sample-to-sample variation of LC/MS 
sensitivity and has pinpointed specific GAG structural 
changes in adducted thumb-clubfoot syndrome patient 
fibroblasts.79 We expect that serum/plasma GAG-based 
biomarker discovery will be enabled by this method.
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